UBS Group’s Revelation Biosciences Warrant REVBW Stock Holding History

UBS Group’s Portfolio REVBW Stock Details REVBW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4	Buy	+532	New	+$5	﹤0.01%	10364
2025 Q4	–	Sell	-1,133	Closed	-$12	–	11063
2025 Q3	$12	Sell	1,133 -167	-13%	-$2	﹤0.01%	10174
2025 Q2	$16	Buy	1,300 +1,028	+378%	+$12	﹤0.01%	10133
2025 Q1	$3	Sell	272 -2,240	-89%	-$34	﹤0.01%	10150
2024 Q4	$18	Sell	2,512 -156	-6%	-$2	﹤0.01%	9780
2024 Q3	$40	Sell	2,668 -2,047	-43%	-$29	﹤0.01%	9255
2024 Q2	$94	Buy	+4,715	New	+$77	﹤0.01%	9172
2023 Q4	–	Sell	-78,000	Closed	-$1.33K	–	9790
2023 Q3	$1.33K	Buy	+78,000	New	+$1.29K	﹤0.01%	7985
2023 Q2	–	Sell	-6,089	Closed	-$97	–	9515
2023 Q1	$97	Buy	+6,089	New	+$153	﹤0.01%	9250
2022 Q4	–	Sell	-5,124	Closed	–	–	11065
2022 Q3	$0	Sell	5,124 -13,631	-73%	-$1.11K	﹤0.01%	10824
2022 Q2	$2K	Buy	18,755 +12,336	+192%	+$1.03K	﹤0.01%	9606
2022 Q1	$1K	Sell	6,419 -421	-6%	-$108	﹤0.01%	9909
2021 Q4	$5K	Buy	+6,840	New	+$4.19K	﹤0.01%	9412
2021 Q3	–	Sell	-1,015	Closed	-$1K	–	9989
2021 Q2	$1K	Sell	1,015 -302	-23%	-$180	﹤0.01%	9181
2021 Q1	$1K	Buy	+1,317	New	+$1.23K	﹤0.01%	8791

Other funds holding REVBW

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

PVI

Pine Valley Investments Marlton, New Jersey $2.18B AUM 26.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SIA

Soltis Investment Advisors St. George, Utah $1.59B AUM 23.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

QWM

Quaker Wealth Management Moorestown, New Jersey $320M AUM 13.7% 1-Year Est. Return

UBS Group's REVBW Position: Q1 2026 in Review

UBS Group opened a new position in Revelation Biosciences Warrant (REVBW) in Q1 2026: 532 shares worth $4. The stake represents ﹤0.01% of the portfolio and ranks #10364 among its holdings. This is a return to the name: UBS Group previously reported a position in REVBW as recently as Q3 2025.

UBS Group first reported a position in REVBW in Q1 2021 and has held it in 15 quarters since. The position peaked at $5K in Q4 2021. 11 funds tracked by Wall St. Rank hold REVBW as of Q1 2026.

UBS Group held 532 shares of Revelation Biosciences Warrant worth $4 as of Q1 2026.
Revelation Biosciences Warrant was a new UBS Group position in Q1 2026.
Revelation Biosciences Warrant made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10364 holding.
UBS Group first reported a position in Revelation Biosciences Warrant in Q1 2021 and has held it in 15 quarters since.
UBS Group's Revelation Biosciences Warrant position peaked at $5K in Q4 2021.
11 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.